Discontinuation of empirical antibiotic therapy in neutropenic acute myeloid leukaemia patients with fever of unknown origin: Is it ethical?

Clinical Microbiology and Infection

Volumn 20, Issue 7, 2014, Pages

  Micol, J B ^a   Chahine, C ^a   Woerther, P L ^a   Ghez, D ^a   Netzer, F ^a   Dufour, C ^a   Merad, M ^a   Blot, F ^a   Chachaty, E ^a   de Botton, S ^a   Gachot, B ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

Acute myeloid leukaemia; Antibiotic discontinuation; Bacterial resistance; Fever of unknown origin; Neutropenia

Indexed keywords

ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ANTIBIOTIC THERAPY; ARTICLE; BACTEREMIA; BACTERIAL STRAIN; CLINICAL ARTICLE; DISEASE DURATION; HUMAN; INTENSIVE CARE UNIT; MIDDLE AGED; NEUTROPENIA; PRIORITY JOURNAL; PYREXIA IDIOPATHICA; RECURRENT FEVER; SEPTIC SHOCK; COMPLICATION; ETHICS; FEMALE; FEVER OF UNKNOWN ORIGIN; MALE; TREATMENT OUTCOME; TREATMENT WITHDRAWAL;

BACTERIA (MICROORGANISMS);

ADULT; AGED; ANTI-BACTERIAL AGENTS; FEMALE; FEVER OF UNKNOWN ORIGIN; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; NEUTROPENIA; TREATMENT OUTCOME; WITHHOLDING TREATMENT;

EID: 84905030198     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1111/1469-0691.12445     Document Type: Article

References (15)

1. Abdel-Wahab O, Levine RL. Mutations in epigenetic modifiers in the pathogenesis and therapy of acute myeloid leukemia. Blood 2013; 18: 3563-3572.
2. Burnett AK. Treatment of acute myeloid leukemia: are we making progress? Hematology Am Soc Hematol Educ Program 2012; 2012:1-6.
3. Cannas G, Pautas C, Raffoux E et al. Infectious complications in adult acute myeloid leukemia: analysis of the Acute Leukemia French Association-9802 prospective multicenter clinical trial. Leuk Lymphoma 2012; 53: 1068-1076.
4. Ben-David D, Kordevani R, Keller N et al. Outcome of carbapenem resistant Klebsiella pneumoniae bloodstream infections. Clin Microbiol Infect 2012; 18: 54-60.
5. Horowitz HW, Holmgren D, Seiter K. Stepdown single agent antibiotic therapy for the management of the high risk neutropenic adult with hematologic malignancies. Leuk Lymphoma 1996; 2: 159-163.
6. Joshi JH, Schimpff SC, Tenney JH, Newman KA, de Jongh CA. Can antibacterial therapy be discontinued in persistently febrile granulocytopenic cancer patients? Am J Med 1984; 76: 450-457.
7. Cherif H, Björkholm M, Engervall P et al. A prospective, randomized study comparing cefepime and imipenem-cilastatin in the empirical treatment of febrile neutropenia in patients treated for haematological malignancies. Scand J Infect Dis 2004; 36: 593-600.
8. Cornelissen JJ, Rozenberg-Arska M, Dekker AW. Discontinuation of intravenous antibiotic therapy during persistent neutropenia in patients receiving prophylaxis with oral ciprofloxacin. Clin Infect Dis 1995; 21: 1300-1302.
9. Slobbe L, Waal L, Jongman LR, Lugtenburg PJ, Rijnders BJ. Three-day treatment with imipenem for unexplained fever during prolonged neutropaenia in haematology patients receiving fluoroquinolone and fluconazole prophylaxis: a prospective observational safety study. Eur J Cancer 2009; 45: 2810-2817.
10. Bucaneve G, Micozzi A, Menichetti F et al. Levofloxacin to prevent bacterial infection in patients with cancer and neutropenia. N Engl J Med 2005; 10: 977-987.
11. Montassier E, Batard E, Gastinne T, Potel G, de La Cochetiére MF. Recent changes in bacteremia in patients with cancer: a systematic review of epidemiology and antibiotic resistance. Eur J Clin Microbiol Infect Dis 2013; 32: 841-850.
12. Pizzo PA. Management of fever in patients with cancer and treatment-induced neutropenia. N Engl J Med 1993; 18: 1323-1332.
13. Pizzo PA, Robichaud KJ, Gill FA et al. Duration of empiric antibiotic therapy in granulocytopenic patients with cancer. Am J Med 1979; 67: 194-200.
14. Taur Y, Pamer EG. The intestinal microbiota and susceptibility to infection in immunocompromised patients. Curr Opin Infect Dis 2013; 26: 332-337.
15. Freifeld AG, Bow EJ, Sepkowitz KA et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of america. Clin Infect Dis 2011; 4: e56-e93.